Market Impact of AI-Discovered Drugs Entering Phase 3 Clinical Trials

Insilico Medicine's idiopathic pulmonary fibrosis (IPF) treatment candidate, Rentosertib (INS018_055), has entered Phase 3 clinical trials in China, marking a significant step towards demonstrating the efficacy of AI-driven drug development. Rentosertib is an inhibitor of TNIK (Traf2- and NCK-interacting kinase), a novel target identified by AI, and is expected to significantly improve lung function compared to existing standard treatments like Nintedanib and Pirfenidone. With the global IPF market estimated at $4 billion to $5 billion by 2025-2026, the success of this Phase 3 trial will be a pivotal moment, not only for Insilico's corporate value but also for the overall credibility of AI platforms in the industry. If the Forced Vital Capacity (FVC) improvement data observed in Phase 2a trials is replicated in a larger patient population, the valuation of AI-based biotech companies could reach unprecedented levels.

Recursion's Clinical Success and the Resilience of its Platform Technology

Recursion Pharmaceuticals (RXRX) underwent restructuring following clinical failures in its Cerebral Cavernous Malformation (CCM) and Neurofibromatosis Type II (NF2) pipelines but has recently achieved a significant turnaround. REC-4881, a MEK1/2 inhibitor in-licensed from Takeda Pharmaceuticals, has shown promising results in a Phase 1b/2 trial for Familial Adenomatous Polyposis (FAP), reducing polyp burden by 43% in patients. In a market where there are no approved treatments other than total colectomy, the emergence of REC-4881 offers patients a potentially groundbreaking non-surgical alternative. Despite past clinical failures that raised some technical skepticism, this clinical success demonstrates that AI platforms are powerful tools not only for identifying promising drug candidates but also for repositioning them for optimal indications.

Lessons from Verge Genomics' Failure and Associated Risks

However, not all AI-driven drugs are guaranteed to succeed, and the case of Verge Genomics serves as a stark warning to the industry. Verge Genomics' ALS treatment candidate, VRG50635, which was discovered using its proprietary AI platform CONVERGE, failed to demonstrate efficacy in an early clinical trial (Phase 1/1b) and its development was discontinued. Although it was designed as a PIKfyve inhibitor to restore endolysosome function, a cellular waste disposal system, it ultimately failed to control the complex biological mechanisms in the human body. This clearly illustrates the significant gap between in silico predictions and the biological reality in actual clinical settings, and it suggests that investors need to conduct thorough, data-driven validation.

Restructuring of Partnership Agreements with Major Pharmaceutical Companies

Success or failure in clinical trials is ultimately redefining the partnership and licensing agreements between major pharmaceutical companies (Big Pharma) and AI biotech companies. For example, Insilico Medicine's agreement with Exelixis for USP1 inhibitor ISM3091 (XL309) includes an upfront payment of $80 million, plus milestones and royalties, and this structure is becoming increasingly common. Major pharmaceutical companies are increasingly inclined to base their deals on objective safety and efficacy data obtained in Phase 1 and Phase 2 trials, rather than simply on technological potential.

Consequently, AI platform companies must evolve from being mere technology providers to becoming comprehensive biotech companies with in-house clinical capabilities in order to gain recognition for their true value in the market.